MPO and pulmonary fibrosis: Mogroside IIIE (41) has the greatest inhibitory activity on NO (an important inflammatory factor) release from LPS-induced RAW264.7 cells, eliminating pulmonary fibrosis and demonstrating a decrease in myeloperoxidase (MPO) activity, collagen deposition and pathology scores.